Curioler — home
Behaviour
Tier 1 · Strong research evidence

Why this tier: Systematic review or meta-analysis

Systematic review

Managing hyperactivity in autistic children: medicines, therapies and what the evidence supports

Published 18 September 2026 · 5 min read

9 reads

Across many trials, two medicines also used for ADHD, methylphenidate and atomoxetine, eased overactivity and trouble paying attention in autistic children. Regular exercise helped behavior, parent coaching helped with difficult behavior at home, and melatonin helped sleep, which often feeds daytime restlessness. Omega-3 supplements and sensory therapies had much weaker support. Most of the studies were small and short, so the evidence is rated low quality.

What this research found

  • Researchers usually study hyperactivity in autistic children as ADHD (attention deficit hyperactivity disorder) that comes alongside the autism. That is common in autism, and it makes daily life noticeably harder.
  • Medicines have the strongest direct evidence. Methylphenidate, a stimulant medicine, cut hyperactivity by a moderate to large amount, as rated by both parents and teachers. Atomoxetine, a non-stimulant, reduced hyperactivity and trouble paying attention as rated by parents. Sometimes it also eased repeated movements and pulling away from other people.
  • Guanfacine, in a slow-release form, reduced hyperactivity, irritability and repeated behaviors. This was seen in a trial of 62 children that compared it with a placebo (a dummy pill), and in a 2025 study of 29 children across several clinics. It is often used when a child does not cope well with stimulants.
  • Exercise is the therapy with the most support. When researchers combined the results of 23 trials, exercise brought a moderate drop in behavior problems, with martial arts and ball games standing out. A separate look at 11 trials found better self-control, the skill behind "stop and think".
  • Parent training helps, but only with some things. In parent training, parents are coached in how to respond to difficult behavior. A 24-week trial found it did better than parent education (information for parents, without the coaching) for disruptive behavior at home. The authors said it was unclear how much difference this made in daily life. In another trial that paired it with atomoxetine, parent training on its own did no better than a placebo on the main ADHD signs (overactivity, trouble focusing, acting on impulse) over four weeks.
  • Treating sleep is an indirect route, but a well-supported one. Melatonin reliably helps autistic children fall asleep faster and sleep longer, with mild side effects. Poor sleep is a common cause of restlessness during the day.
  • Omega-3 supplements gave a small drop in hyperactivity across 6 trials. The result was borderline, meaning it could be down to chance. It was several times weaker than methylphenidate or risperidone, another prescription medicine, on the same rating scale. It did have far fewer side effects.
  • Sensory integration therapy uses play and movement to help a child handle sound, touch and motion. It and other occupational therapy approaches (help with everyday skills and activities) are widely used. But reviews of them report mixed, low-quality evidence for reducing hyperactivity in particular.
  • The side effects in the medicine trials were mostly trouble sleeping, eating less, irritability and stomach upset. Sleepiness and dizziness were more typical of guanfacine.

What this means for caregivers

  • There is a real therapy route worth trying, as well as a medicine route. Regular, structured physical activity has the best evidence of the options that do not involve medicine. It is low risk and fits into ordinary family life.
  • Think about what each approach is for. Medicines aim most directly at hyperactivity. Parent training aims at difficult behavior at home, and gives you more ways to respond. Exercise supports self-control and behavior more broadly. Melatonin helps sleep, which may be feeding the restlessness.
  • Before anything else, or alongside it, check whether something else is behind the hyperactivity. Poor sleep, anxiety, pain, sensory overload (too much noise, light or touch) or a classroom that does not suit your child can all drive it, and each has its own fixes.
  • If hyperactivity is still a big difficulty, it is reasonable to ask whether an ADHD assessment would help. Most of the medicine evidence is about children who have ADHD as well as autism, so that assessment is usually the way in.
  • Medicine is not one single decision. Methylphenidate had the strongest effect when the trials were combined. Atomoxetine and guanfacine are alternatives when a child does not cope well with stimulants. Expect to try, review and adjust, not a guaranteed result.
  • Ask your child's doctor what will be checked and when. Appetite, sleep, irritability, weight, heart rate and blood pressure all came up in these trials as things to watch.
  • Be cautious with supplements sold for hyperactivity. Omega-3 shows a real but small effect. Most other products sold for this have not been tested in trials with autistic children at all.

Important caveats

  • This is a summary of research, not medical advice. Decisions about medicine belong with your child's doctor, who knows their full history.
  • The evidence was graded low to very low quality. That does not mean these treatments do not work. It means the studies were few, small and short, and the conclusions could change.
  • Therapy trials are especially open to expectation effects, where people rate a child as better because they expect the program to help. Parents and teachers usually know which children got the program. In wider ADHD research, the gains from behavior-based therapies shrink a lot once the people rating the child do not know who got it.
  • "Exercise" and "parent training" are broad labels that cover very different programs. A service near you may not match what was tested.
  • How big each effect was comes from rating scales. These are questionnaires that capture people's impressions, not objective measurements.
  • Children in these trials were mostly ones without a significant intellectual disability (major difficulty with learning and reasoning). So the findings may not describe how every child would respond.

The science behind it

This part is written for researchers, so it gets technical. Reading it anyway is what researchers do: checking how a finding was reached, not just what it says. It’s slow going at first and gets easier after your first few articles. Skipping it is fine too.

A meta-analysis of 25 randomized trials found methylphenidate and atomoxetine reduce hyperactivity and inattention in autistic children, with small-to-moderate effects. On the therapy side, a meta-analysis of 23 exercise trials found a moderate reduction in behavioral problems, parent training beat parent education for disruptive behavior at home over 24 weeks, and melatonin reliably improves sleep, which often drives daytime restlessness. Omega-3 and sensory integration have much weaker support, and evidence quality across the board is rated low.

At a glance

Sample size: Medicines: 25 RCTs pooled (plus a 2025 review of 32 studies). Therapies: 23 exercise RCTs, 11 physical-activity RCTs (346 children), a 24-week parent training RCT, and 6 omega-3 RCTs (194 children)
Demographics: Children and young people with autism spectrum disorder, mostly aged 3-18; medication trials generally ran under 25 years and often excluded children with significant intellectual disability
Key outcome: Methylphenidate reduced hyperactivity by a standardized mean difference of -0.63 (parent-rated) and -0.81 (teacher-rated); atomoxetine -0.49 parent-rated. Exercise interventions reduced behavioral problems by SMD -0.674 across 23 RCTs. Omega-3 produced only a small, borderline effect on hyperactivity (Hedges g = -0.35, confidence interval crossing zero).
Methodology: Several systematic reviews and meta-analyses of randomized controlled trials, pooled with random-effects models. Medication effects come from parent and teacher rating scales; therapy effects come from trials of exercise programs, behavioral parent training, supplements and sleep treatment, each pooled separately.
Researchers: Rebecca Rodrigues, Meng-Chuan Lai, Stephanie H Ameis, Carmela De Domenico, Francesca Cucinotta, Karen Bearss, Lawrence Scahill, David Daley
Institutes: Western University, Canada, Centre for Addiction and Mental Health, Toronto, The Hospital for Sick Children, Toronto, Autism Research Centre, University of Cambridge, Emory University, IRCCS Centro Neurolesi Bonino-Pulejo, Messina

Limitations:

  • Only a handful of medication trials existed per drug (4 for methylphenidate, 4 for atomoxetine), and most were small and short
  • Overall quality of evidence was rated low to very low, so future trials could change these numbers
  • No trial examined long-term continued use, which is how these medicines are usually taken
  • Most outcomes rest on parent and teacher questionnaires rather than direct observation, and raters are often not blind to treatment
  • Exercise and parent training trials are hard to blind, so their effects are likely flattered by rater expectations; in ADHD research, behavioral intervention effects shrink sharply when blinded measures are used
  • Therapy trials were mostly small, short, and varied widely in what they delivered, so 'exercise' or 'parent training' covers very different programs
  • Trials rarely included autistic children with significant intellectual disability or minimal speech, so findings may not transfer to every child

About this research

The medication findings rest on a practitioner review in the Journal of Child Psychology and Psychiatry (2021) that pooled 25 randomized controlled trials, supported by a 2025 PROSPERO-registered systematic review in the Journal of Clinical Medicine covering 32 studies. The therapy findings draw on a 2025 meta-analysis of 23 exercise trials, a meta-analysis of 11 physical-activity trials in children with ADHD and/or autism, a randomized trial of 24-week parent training versus parent education, a meta-analysis of 6 omega-3 trials, and meta-analyses of melatonin for sleep in autism. The reviews agree on direction, which strengthens confidence, but nearly all rate the underlying trial quality as low.

The research in its own terms. The findings above are written without some of the papers' terms. Here they are, so you can match them to the papers:

  • Atomoxetine: reduced parent-rated hyperactivity and inattention, sometimes also stereotyped behavior and social withdrawal.
  • Guanfacine: extended-release guanfacine, in a placebo-controlled trial of 62 children and a 2025 multi-center clinic study of 29 children; often used when stimulants are not tolerated.
  • Exercise: the meta-analysis pooled 23 randomized and quasi-randomized trials (behavioral problems, SMD -0.674); the separate pooling of 11 trials found gains in inhibitory control.
  • Parent training: behavioral parent training beat parent education for disruptive behavior at home in a 24-week randomized trial, though the authors noted the clinical significance was unclear. In the trial pairing it with atomoxetine, parent training alone did not separate from placebo on core ADHD symptoms over four weeks.
  • Omega-3: a small, borderline effect across 6 trials (Hedges g = -0.35, confidence interval crossing zero).

Sources

Related topics

This summary was prepared by the Curioler research agent. It is not medical advice. Always consult a qualified professional before making decisions about your child's care.

Reviewed by Bhavin Solanki, caregiver parent. This is informational content, not medical advice — see our disclaimer.